Maravai LifeSciences Presents 20% Growth in Year-to-Date Revenue to $163.1 Million

PUBT · 2d ago
Maravai LifeSciences Presents 20% Growth in Year-to-Date Revenue to $163.1 Million
  • Maravai LifeSciences reported year-to-date 2026 revenue of $163.1 million, up 20%, in an investor presentation.
  • Adjusted EBITDA reached $34.8 million, with an adjusted gross margin of 61.1%.
  • TriLink base revenue rose 13% year over year, driven by mRNA growth; Cygnus revenue increased 4%, its sixth consecutive quarterly gain.
  • Cost reductions exceeded $65 million under the corporate realignment plan, surpassing the initial target of more than $50 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.